Screening Anti-Fungal Exposure in Intensive Care Units – The French Cohort - French SAFE ICU Study

CHU de NIMES0 个研究点目标入组 40 人开始时间: 2024年4月23日最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•Critically ill patients requiring ICU care
•Receiving systemic therapy of antifungal of interest (triazole, echinocandin, amphotericin) including prophylaxis indication and antifungal therapy started in another unit (wards, operating room) for the same infectious episode
•Availability of suitable intravenous/intra-arterial access to facilitate sample collection
•Written informed consent has been obtained from the patient or their next of kin or the patient has been included in emergency situation
•The patient must be insured or beneficiary of a health insurance plan
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 20

•Aged < 18 years of age
•Consent not obtained (except in emergency situation)
•Diagnosis with human immunodeficiency virus or hepatitis B or C or tuberculosis

发起方

CHU de NIMES